HALMED flagged procedural GMP observations at Eris Swiss Parenterals Units 1 and 2. Remediation and CAPA implementation are planned, with a follow-up inspection sought. Minimal direct business impact anticipated, but EU-CDMO product pipeline commercialization may be delayed.